Monopar Therapeutics Inc.
NASDAQ: MNPR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Chandler D. Robinson
- Employees
- 22
- Headquarters
- Wilmette, United States
- IPO year
- 2019
- Market cap
- $596.1M
- Website
- https://www.monopartx.com
Loading MNPR…
Loading profile data…Frequently asked questions about MNPR
What does Monopar Therapeutics Inc. (MNPR) do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotope...
Where does MNPR trade?
Monopar Therapeutics Inc. (MNPR) trades on the NASDAQ.
What sector is MNPR in?
Monopar Therapeutics Inc. (MNPR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Monopar Therapeutics Inc.?
Chandler D. Robinson is the chief executive officer of Monopar Therapeutics Inc. (MNPR).
Where is Monopar Therapeutics Inc. headquartered?
Monopar Therapeutics Inc. is headquartered in United States.
Does MNPR pay a dividend?
Monopar Therapeutics Inc. (MNPR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MNPR go public?
Monopar Therapeutics Inc. (MNPR) completed its initial public offering in 2019.